Besekar Smruti M, Jogdand Sangita D, Naqvi Waqar M
Pharmacology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha, IND.
Research, Humen Edutech, Nagpur, IND.
Cureus. 2023 Mar 28;15(3):e36811. doi: 10.7759/cureus.36811. eCollection 2023 Mar.
Statins are the most widely used drugs for reducing lipid and cholesterol levels in the blood. However, statins have shown some adverse effects and less acceptance among patients; hence, new drugs have been promoted in the market. Furthermore, gemcabenes were discovered in 1995 and are now in phase II and III clinical trials. Gemcabene acts by inhibiting incorporation of 14C-acetate into hepatocytes and stops the mechanism of fatty acids and cholesterol synthesis. In this review the six randomized controlled trials (RCTs) were scrutinized from the two databases by using keywords "Gemcabene" AND "Randomized Controlled Trial." The trials were mainly on animal models, and two studies were found to be associated with human subjects. The study concluded that gemcabene was effective as an anti-inflammatory agent and reduced lipid levels and the progression of fibrosis. Hence, further controlled trials are needed to determine its efficacy and safety in human subjects, along with the identification of adverse effects.
他汀类药物是用于降低血液中脂质和胆固醇水平的应用最为广泛的药物。然而，他汀类药物已显示出一些不良反应，且患者接受度较低；因此，市场上已推出了新药。此外，吉卡贝尼于1995年被发现，目前正处于II期和III期临床试验阶段。吉卡贝尼通过抑制14C-乙酸盐掺入肝细胞来发挥作用，并阻断脂肪酸和胆固醇的合成机制。在本综述中，通过使用关键词“吉卡贝尼”和“随机对照试验”，从两个数据库中仔细审查了六项随机对照试验（RCT）。这些试验主要针对动物模型，发现有两项研究与人类受试者相关。该研究得出结论，吉卡贝尼作为一种抗炎药是有效的，可降低脂质水平并减缓纤维化进程。因此，需要进一步的对照试验来确定其在人类受试者中的疗效和安全性，同时识别不良反应。
